Angion Biomedica Corp:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Angion Biomedica Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C3031)・商品コード:DATA904C3031
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:18
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Angion Biomedica Corp (Angion) is a clinical-stage organ restoration biopharmaceutical company that discovers and develops novel treatments for the treatment of renal and chronic organ injury and disease. The company’s pipeline products include BB3, ANG-3070, ANG-3586, ANG-4201, TBD and ANG-4102. Its BB3 is a HGF-like small molecule compound, which is used to treat various indications such as acute kidney injury, renal transplantation and delayed graft function. Angion’s ANG-3070, is a fibrokinase inhibitor which is being developed to treat chronic renal disease. It also conducts preclinical development programs in chronic kidney disease including diabetic nephropathy and polycystic kidney disease. The company operates through its research and development facility located in New York. Angion is headquartered in Uniondale, New York, the US.

Angion Biomedica Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Angion Biomedica Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Angion Biomedica Enters into Licensing Agreement with ElexoPharm 10
Angion Biomedica Enters into Licensing Agreement with Ohr Cosmetics for ANG-3522 11
Equity Offering 12
Angion Biomedica Withdraws IPO 12
Angion Biomedica Corp – Key Competitors 14
Angion Biomedica Corp – Key Employees 15
Angion Biomedica Corp – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Corporate Communications 17
Sep 07, 2017: Angion Biomedica Expands Personnel with New Director of Discovery and Medicinal Chemistry, and Director of Clinical Operations 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Key Facts 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Angion Biomedica Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Angion Biomedica Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Angion Biomedica Enters into Licensing Agreement with ElexoPharm 10
Angion Biomedica Enters into Licensing Agreement with Ohr Cosmetics for ANG-3522 11
Angion Biomedica Withdraws IPO 12
Angion Biomedica Corp, Key Competitors 14
Angion Biomedica Corp, Key Employees 15

List of Figures
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Angion Biomedica Corp:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C3031)販売に関する免責事項を必ずご確認ください。
★調査レポート[Angion Biomedica Corp:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆